Retrovirus-induced lymphoproliferative disease in mice: role of humoral immunity in perinatally exposed mice. 1995

M B Zaleski, and H R Thacore, and P Zhou, and S Dubiski, and S Nakeeb, and R K Cunningham
Department of Microbiology, Toronto, Ontario, Canada.

The mice born to female mice infected with LP-BM5 MuLV, the etiologic agent for lymphoproliferative disease and nursed for 4-6 weeks by them were less susceptible upon reinfection by i.v. transfusion of blood or plasma from infected donors with fully developed disease. Sera of 7 week or older perinatally exposed mice were capable of a complete in vitro neutralization of virus in plasma or blood from mice with fully developed disease. In contrast, sera from 3-week old perinatally exposed mice were ineffective. The neutralizing ability of the sera was drastically reduced or abrogated after their absorption with anti-mouse IgM. These observations are consistent with the notion that perinatally exposure results ina moderate form of the disease of the offspring. This perinatal infection is followed by a production of neutralizing antibodies of predominantly the IgM class that significantly alters the course of the lymphoproliferative disease and, in some instances, even prevents its development.

UI MeSH Term Description Entries
D007112 Immunity, Maternally-Acquired Resistance to a disease-causing agent induced by the introduction of maternal immunity into the fetus by transplacental transfer or into the neonate through colostrum and milk. Fetal Immunity, Maternally-Acquired,Maternally-Acquired Immunity,Neonatal Immunity, Maternally-Acquired,Immunity, Maternally Acquired,Fetal Immunities, Maternally-Acquired,Fetal Immunity, Maternally Acquired,Immunity, Maternally-Acquired Fetal,Immunity, Maternally-Acquired Neonatal,Maternally Acquired Immunities,Maternally Acquired Immunity,Maternally-Acquired Fetal Immunities,Maternally-Acquired Fetal Immunity,Maternally-Acquired Immunities,Maternally-Acquired Neonatal Immunities,Maternally-Acquired Neonatal Immunity,Neonatal Immunities, Maternally-Acquired,Neonatal Immunity, Maternally Acquired
D007113 Immunity, Innate The capacity of a normal organism to remain unaffected by microorganisms and their toxins. It results from the presence of naturally occurring ANTI-INFECTIVE AGENTS, constitutional factors such as BODY TEMPERATURE and immediate acting immune cells such as NATURAL KILLER CELLS. Immunity, Native,Immunity, Natural,Immunity, Non-Specific,Resistance, Natural,Innate Immune Response,Innate Immunity,Immune Response, Innate,Immune Responses, Innate,Immunity, Non Specific,Innate Immune Responses,Native Immunity,Natural Immunity,Natural Resistance,Non-Specific Immunity
D008232 Lymphoproliferative Disorders Disorders characterized by proliferation of lymphoid tissue, general or unspecified. Duncan's Syndrome,X-Linked Lymphoproliferative Syndrome,Duncan Disease,Epstein-Barr Virus Infection, Familial Fatal,Epstein-Barr Virus-Induced Lymphoproliferative Disease In Males,Familial Fatal Epstein-Barr Infection,Immunodeficiency 5,Immunodeficiency, X-Linked Progressive Combined Variable,Lymphoproliferative Disease, X-Linked,Lymphoproliferative Syndrome, X-Linked, 1,Purtilo Syndrome,X-Linked Lymphoproliferative Disease,X-Linked Lymphoproliferative Disorder,Disease, Duncan,Disease, X-Linked Lymphoproliferative,Diseases, X-Linked Lymphoproliferative,Disorder, Lymphoproliferative,Disorder, X-Linked Lymphoproliferative,Disorders, Lymphoproliferative,Disorders, X-Linked Lymphoproliferative,Epstein Barr Virus Induced Lymphoproliferative Disease In Males,Epstein Barr Virus Infection, Familial Fatal,Familial Fatal Epstein Barr Infection,Immunodeficiency 5s,Immunodeficiency, X Linked Progressive Combined Variable,Lymphoproliferative Disease, X Linked,Lymphoproliferative Diseases, X-Linked,Lymphoproliferative Disorder,Lymphoproliferative Disorder, X-Linked,Lymphoproliferative Disorders, X-Linked,Lymphoproliferative Syndrome, X-Linked,Lymphoproliferative Syndromes, X-Linked,Purtilo Syndromes,Syndrome, Purtilo,Syndrome, X-Linked Lymphoproliferative,Syndromes, Purtilo,Syndromes, X-Linked Lymphoproliferative,X Linked Lymphoproliferative Disease,X Linked Lymphoproliferative Disorder,X Linked Lymphoproliferative Syndrome,X-Linked Lymphoproliferative Diseases,X-Linked Lymphoproliferative Disorders,X-Linked Lymphoproliferative Syndromes
D008297 Male Males
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D009052 Leukemia Virus, Murine Species of GAMMARETROVIRUS, containing many well-defined strains, producing leukemia in mice. Disease is commonly induced by injecting filtrates of propagable tumors into newborn mice. Graffi Virus,Graffi's Chloroleukemic Strain,Leukemia Viruses, Murine,Mouse Leukemia Viruses,Murine Leukemia Virus,Murine Leukemia Viruses,Graffi Chloroleukemic Strain,Graffis Chloroleukemic Strain,Leukemia Viruses, Mouse
D005260 Female Females
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000831 Animals, Newborn Refers to animals in the period of time just after birth. Animals, Neonatal,Animal, Neonatal,Animal, Newborn,Neonatal Animal,Neonatal Animals,Newborn Animal,Newborn Animals
D000914 Antibodies, Viral Immunoglobulins produced in response to VIRAL ANTIGENS. Viral Antibodies

Related Publications

M B Zaleski, and H R Thacore, and P Zhou, and S Dubiski, and S Nakeeb, and R K Cunningham
April 1988, Canadian journal of veterinary research = Revue canadienne de recherche veterinaire,
M B Zaleski, and H R Thacore, and P Zhou, and S Dubiski, and S Nakeeb, and R K Cunningham
March 2013, Immunologic research,
M B Zaleski, and H R Thacore, and P Zhou, and S Dubiski, and S Nakeeb, and R K Cunningham
November 1984, Toxicology letters,
M B Zaleski, and H R Thacore, and P Zhou, and S Dubiski, and S Nakeeb, and R K Cunningham
January 1994, Virology,
M B Zaleski, and H R Thacore, and P Zhou, and S Dubiski, and S Nakeeb, and R K Cunningham
January 1980, Medicinski pregled,
M B Zaleski, and H R Thacore, and P Zhou, and S Dubiski, and S Nakeeb, and R K Cunningham
May 1992, AIDS research and human retroviruses,
M B Zaleski, and H R Thacore, and P Zhou, and S Dubiski, and S Nakeeb, and R K Cunningham
July 2014, Epigenetics,
M B Zaleski, and H R Thacore, and P Zhou, and S Dubiski, and S Nakeeb, and R K Cunningham
June 1993, Journal of virology,
M B Zaleski, and H R Thacore, and P Zhou, and S Dubiski, and S Nakeeb, and R K Cunningham
December 2005, Infection and immunity,
M B Zaleski, and H R Thacore, and P Zhou, and S Dubiski, and S Nakeeb, and R K Cunningham
October 2023, Current opinion in organ transplantation,
Copied contents to your clipboard!